Cargando…

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and highly resistant to available chemotherapies. Mammalian target of rapamycin (mTOR) functions to regulate protein translation, angiogenesis and cell cycle progression in many cancers including HCC. In the present study,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huynh, Hung, Pierce Chow, KH, Soo, Khee Chee, Toh, Han Chong, Choo, Su Pin, Foo, Kian Fong, Poon, Donald, Ngo, Van Chanh, Tran, Evelyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2009
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496150/ https://www.ncbi.nlm.nih.gov/pubmed/18466352 http://dx.doi.org/10.1111/j.1582-4934.2008.00364.x

Ejemplares similares

Everolimus (RAD001) in the Treatment of Advanced Renal Cell Carcinoma: A Review
por: Agarwala, Sanjiv S., et al.
Publicado: (2010)

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
por: Lim, Taekyu, et al.
Publicado: (2011)

Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells
por: Tai, Sheng, et al.
Publicado: (2017)

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib
por: Juengel, Eva, et al.
Publicado: (2015)

The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells
por: Kuwatsuka, Y, et al.
Publicado: (2011)

Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1
por: Alshaker, Heba, et al.
Publicado: (2016)

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1
por: Alshaker, Heba, et al.
Publicado: (2017)

Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
por: Lau, David K., et al.
Publicado: (2018)

Everolimus (RAD001) inhibits the proliferation of rat vascular smooth muscle cells by up-regulating the activity of the p27/kip1 gene promoter
por: Ran, Boli, et al.
Publicado: (2016)

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression
por: Park, Ji Hyun, et al.
Publicado: (2015)

Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer
por: Bradshaw-Pierce, Erica L., et al.
Publicado: (2013)

Dataset of vaccination and confidence in the Malaysian government during Covid-19 pandemic
por: Pek, Chuen Khee, et al.
Publicado: (2022)

Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma
por: Ang, Soo Fan, et al.
Publicado: (2015)

The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma
por: Ang, Soo Fan, et al.
Publicado: (2015)

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models
por: Owonikoko, Taofeek K., et al.
Publicado: (2019)

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis
por: Huynh, Hung, et al.
Publicado: (2003)

Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells
por: Lin, Ji-Fan, et al.
Publicado: (2016)

The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor
por: Pan, Jie, et al.
Publicado: (2020)

Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway
por: Gao, Feng, et al.
Publicado: (2022)

Renal pelvis squamous cell carcinoma with inferior vena cava infiltration: Case report and review of the literature
por: Lin, Zhimin, et al.
Publicado: (2014)

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
por: Nyfeler, Beat, et al.
Publicado: (2012)

NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer
por: Das, Kakoli, et al.
Publicado: (2016)

Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro
por: Awad, Eman, et al.
Publicado: (2017)

RAD001 targeted HUVECs reverses 12‐lipoxygenase‐induced angiogenesis in oesophageal squamous cell carcinoma
por: Chen, Xue, et al.
Publicado: (2021)

Datasets describing the growth and molecular features of hepatocellular carcinoma patient-derived xenograft cells grown in a three-dimensional macroporous hydrogel
por: Fong, Eliza Li Shan, et al.
Publicado: (2018)

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy
por: Zhao, Yue, et al.
Publicado: (2018)

Interactions between antifungals and everolimus against Cryptococcus neoformans
por: Liang, Pin, et al.
Publicado: (2023)

Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma
por: Chow, Pierce K. H., et al.
Publicado: (2014)

Effective Inhibition of Xenografts of Hepatocellular Carcinoma (HepG2) by Rapamycin and Bevacizumab in an Intrahepatic Model
por: Ong, Lai-Chun, et al.
Publicado: (2009)

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity
por: Martin, Elizabeth C, et al.
Publicado: (2014)

Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity
por: Lin, Gigin, et al.
Publicado: (2018)

LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
por: Dragowska, Wieslawa H, et al.
Publicado: (2011)

Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
por: Passacantilli, Ilaria, et al.
Publicado: (2014)

Mammalian target of rapamycin inhibitor RAD001 sensitizes endometrial cancer cells to paclitaxel-induced apoptosis via the induction of autophagy
por: Wang, Huan, et al.
Publicado: (2016)

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients
por: Lee, Hansang, et al.
Publicado: (2016)

ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
por: Yeom, Dong-Hoon, et al.
Publicado: (2020)

Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial
por: Gandhi, Mihir, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ua79dlv50udr18vhrpsjtecem9